Method for directionally differentiating sinus node-like cells by inducing embryonic stem cells in vitro

By temporally regulating the combination of BMP signaling pathway and specific culture medium, the differentiation ratio and stability of sinoatrial nodular cells were successfully improved, and the problem of efficient acquisition of high-purity sinoatrial nodular cells in vitro was solved, and the sinoatrial nodular cells were achieved was achieved Efficient differentiation and stability of cells are improved.

CN119020274APending Publication Date: 2024-11-26THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411446136.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

It is difficult for the prior art to efficiently and stably differentiate high-purity sinoatrial nodal-like cells in vitro, and the existing methods have problems with low differentiation ratio, poor stability and low efficiency.

Method used

By temporal and bidirectional regulation of BMP signaling pathway, combined with specific inducible differentiation medium and purification medium, the directed differentiation of embryonic stem cells into sinus node-like cells, including selectively inhibiting the BMP signaling pathway early in differentiation and activation in the later stage. DMH1 and BMP4 recombinant proteins were further purified by sugar-free medium.

Benefits of technology

It significantly improves the differentiation ratio and stability of sinoatrial node-like cells, and can efficiently obtain pacemaker cells with electrophysiological characteristics of sinoatrial nodes in vitro, improving differentiation efficiency and purity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020274A_ABST
    Figure CN119020274A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of cell differentiation, in particular to a method for in-vitro induction of directional differentiation of sinus node-like cells by embryonic stem cells, and provides application of a BMP signal selective inhibitor and a BMP signal activator in induction of in-vitro directional differentiation of sinus node-like cells by embryonic stem cells at the same time. The invention also discloses a reasonable in-vitro differentiation time window and use concentration of the inhibitor and the activator, the differentiation of hESCs to sinus node-like cells is obviously promoted by sequential and bidirectional regulation and control of a BMP signal channel, and pace-making cells with sinus node electrophysiological characteristics can be efficiently obtained in vitro. Meanwhile, the invention discloses a differentiation culture medium and a purification culture medium which are definite in substance, the generation proportion of sinus node-like cells can be remarkably increased, and the defects that in-vitro induction methods need to add various exogenous unknown proteins, and differentiation is unstable and low in efficiency are effectively overcome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of cell differentiation, and in particular to a method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro. Background Art

[0002] The highly coordinated cardiac conduction system (CCS) is the basis for guiding the orderly contraction of the mammalian heart. The mature CCS of mammals includes the sinoatrial node (SAN), atrioventricular node (AVN), atrioventricular bundle and ventricular conduction network. Studies have shown that SAN cells have the highest automaticity and are the main pacemaker site of the heart, providing the main electrical stimulation for each coordinated contraction of the heart. Disorders in SAN development and function lead to sick sinus syndrome (SSS). SSS usually occurs in the elderly, and its prevalence continues to rise in my country. In the United States alone, more than 350,000 pacemaker surgeries are performed each year, of which patients undergoing surgery due to sinus node dysfunction account for more than half of the implantation surgeries.

[0003] At present, the treatment of symptomatic SSS patients mainly relies on implanted electronic pacemakers and symptomatic treatment, and there is a lack of fundamental treatment for the cause. At present, pacemaker cells with a sinoatrial node-like phenotype have been successfully differentiated in vitro through induced pluripotent stem cells. However, most of the current studies are conducted on mixed populations of atrial, ventricular and sinoatrial node-like cardiomyocytes, and the differentiation ratio of sinoatrial node-like cells in the in vitro induction scheme of cardiomyocytes is extremely low. Mixed subtypes of cardiomyocytes may change the phenotype of the disease and affect the prognosis of transplanted cells in vivo. At present, there is a lack of in vitro differentiation methods for sinoatrial node-like cells. It is of great significance to develop a method that can increase the in vitro differentiation ratio of a single subpopulation of sinoatrial node-like cells. Summary of the invention

[0004] The purpose of the present invention is to provide a method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro in order to solve the problems existing in the prior art.

[0005] In order to achieve the above object, the technical solution adopted by the present invention is:

[0006] The application of BMP signaling selective inhibitors and BMP signaling activators in inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro.

[0007] The study found that during the directed differentiation of hESCs into cardiomyocytes, unidirectional inhibition or activation of the BMP signaling pathway can promote the enrichment of sinoatrial node-like cells in vitro. However, through targeted research, it was found that sequential and bidirectional regulation of the BMP signaling pathway significantly promoted the differentiation of hESCs into sinoatrial node-like cells, and could efficiently obtain pacemaker cells with sinoatrial node electrophysiological characteristics in vitro. Selective inhibition of the BMP signaling pathway in the early stages of differentiation and subsequent activation of the BMP signaling pathway can significantly enhance the expression of sinoatrial node genes in the induced cells, greatly inhibit the expression of atrial and ventricular muscles, but also increase the expression of atrioventricular node and non-cardiomyocyte genes to a certain extent. Experimental investigations found that bidirectional regulation of BMP signals (BD) significantly enhanced the expression of sinoatrial node genes in the induced cells, while greatly inhibiting the expression of atrial and ventricular muscles; bidirectional regulation of BMP signals (BD) also significantly increased NKX2.5 - / cTNT + Immunofluorescence staining showed that compared with the GIWI group, the BD group significantly upregulated TBX3 + / cTNT + , SHOX2 + / cTNT + 、TBX18 + / cTNT + and NKX2.5 - / cTNT + proportion.

[0008] Furthermore, the BMP signal selective inhibitor is DMH1; and / or the BMP signal activator is BMP4 recombinant protein.

[0009] Furthermore, the BMP signal selective inhibitor is used on the 4th to 6th day of inducing directed differentiation; the mass concentration of the BMP signal selective inhibitor in the differentiation induction medium is 2-3 μM, preferably, the mass concentration of the BMP signal selective inhibitor in the differentiation induction medium is 2.5 μM.

[0010] Furthermore, the BMP signal activator is used on the 7th to 9th day of inducing directed differentiation; the mass concentration of the BMP signal activator in the differentiation induction medium is 0.5-1 ng / ml, preferably, the mass concentration of the BMP signal activator in the differentiation induction medium is 0.625 ng / ml.

[0011] Another object of the present invention is to provide a differentiation inducing culture medium.

[0012] Previous studies on the in vitro induction methods of sinoatrial node-like cells mainly include gene reprogramming induction method, co-culture induction method and non-gene modification signal pathway induction method. A large number of studies have reported that gene reprogramming induction method can achieve the differentiation of stem cells and even working cardiomyocytes into sinoatrial node-like cells, and successfully constructed a biological pacemaker with pacing function; however, the safety of sinoatrial node-like cells obtained by gene reprogramming has been greatly questioned. In addition, although the conditional induction method of co-culturing stem cells with sinoatrial node tissue blocks or endoderm progenitor cells can successfully induce sinoatrial node-like cells with electrophysiological characteristics and avoid many disadvantages of gene reprogramming to a certain extent; however, this method has little room for improvement in the induction stability and differentiation efficiency of sinoatrial node-like cells, and it is difficult to achieve stable and large-scale acquisition of high-quality and high-purity sinoatrial node-like cells in vitro for subsequent applications.

[0013] The currently used method for monolayer adherent cardiomyocyte differentiation is based on a system of RPMI1640 basal culture medium mixed with "B27" supplement ("B27" supplement is a complex mixture of 21 ingredients, including many unknown proteins of animal origin). It is not clear whether the unknown ingredients in the "B27" supplement will affect the efficiency, maturity and stability of sinoatrial node-like cell differentiation in vitro.

[0014] An induction differentiation medium, the induction differentiation medium comprising differentiation complete medium I, differentiation complete medium II, DMH1 working solution, differentiation complete medium III and BMP4 recombinant protein working solution;

[0015] Among them, differentiation complete medium I includes: RPMI 1640 basal medium, 500 μg / mL L-ascorbic acid 2-phosphate (AA 2-P), 213 μg / mL bovine serum albumin and 5 μM CHIR99021;

[0016] Differentiation complete medium II includes: RPMI 1640 basal medium, 500 μg / mL L-ascorbic acid 2-phosphate (AA2-P), 213 μg / mL bovine serum albumin, and 2 μM Wnt-C59;

[0017] Differentiation complete medium III includes: RPMI 1640 basal medium, 500 μg / mL L-ascorbic acid 2-phosphate (AA 2-P), 213 μg / mL bovine serum albumin;

[0018] The DMH1 working solution is differentiation complete medium III including DMH1 at a mass concentration of 2.5 μM;

[0019] The BMP4 recombinant protein working solution is a differentiation complete medium III including BMP4 recombinant protein at a mass concentration of 0.625 ng / ml.

[0020] The present invention provides an induction differentiation medium, including complete differentiation medium I, complete differentiation medium II, DMH1 working solution, complete differentiation medium III and BMP4 recombinant protein working solution; based on a differentiation medium with clear chemical composition (including basal medium RPMI1640, L-ascorbic acid 2-phosphate and rice-derived recombinant human albumin), up to 95% of cardiomyocytes can be successfully differentiated in vitro. The induction differentiation medium has clear ingredients and has the advantages of simplicity, high efficiency, stability and high repeatability, and effectively overcomes the shortcomings of the in vitro induction method that requires the addition of multiple exogenous unknown proteins, and the differentiation is unstable and inefficient. Another purpose of the present invention is to provide an application of the induction differentiation medium.

[0021] The present invention is based on a differentiation medium with clear chemical composition (including basic medium RPMI1640, L-ascorbic acid 2-phosphate and rice-derived recombinant human albumin) that can successfully differentiate up to 95% of cardiomyocytes in vitro. Compared with the embryoid body induction system and the culture system containing the "B27" additive, the cardiomyocyte basic differentiation program does not add too many cytokines and unknown animal-derived proteins, has the advantages of high efficiency and stability, and can be used as an ideal model for simulating cardiac embryonic development in vitro. This provides a basis for us to develop a differentiation method for sinoatrial node-like cells in vitro.

[0022] The above-mentioned induction differentiation medium is used to induce embryonic stem cells to differentiate into sinoatrial node-like cells in vitro.

[0023] Another object of the present invention is to provide a method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro.

[0024] A method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro,

[0025] Step 1: On differentiation day 0, embryonic stem cells were added to complete differentiation medium I and cultured for 48 h;

[0026] Step 2: On the second day of differentiation, switch to differentiation complete medium II and culture for 48 hours;

[0027] Step 3: On differentiation day 4-6, add 2.5 μM DMH1 working solution to the cells for culture;

[0028] Step 4: On the 6th to 7th day of differentiation, switch to differentiation complete medium III;

[0029] Step 5: On differentiation day 7-9, add 0.625 ng / ml BMP4 recombinant protein working solution to the cells;

[0030] Step 6: From day 9 to day 21, continue culturing using differentiation medium III to obtain differentiated sinoatrial node-like cells.

[0031] The method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro provided by the present invention has simple operation, high differentiation efficiency and is easy to promote and apply.

[0032] Furthermore, the embryonic stem cells are human embryonic stem cells.

[0033] Another object of the present invention is to provide a purification culture medium for differentiated sinoatrial node-like cells.

[0034] There are significant biochemical differences between cardiomyocytes and non-cardiomyocytes (including undifferentiated cells) in glucose and lactate metabolism; non-cardiomyocytes that use glycolysis as their main metabolic mode cannot survive in the absence of glucose, while cardiomyocytes can use lactate as a metabolic substrate for energy metabolism. Early studies observed that isolated, primitive sinoatrial node cells have significant resistance and resilience to prolonged hypoxia and reperfusion; TBX18-induced pacemaker-like cells (iPMs) have almost no death after 2 days of near-anaerobic state and / or glycolysis inhibition. These results indicate that pacemaker-like cells have low metabolic requirements and the ability to tolerate hypoxic stress and glucose deprivation. This allows us to further purify the induced sinoatrial node-like cells in vitro using a glucose-free medium.

[0035] A purification medium for differentiated sinoatrial node-like cells, comprising a purified complete medium I and a purified complete medium II;

[0036] Wherein, the purified complete medium I comprises: RPMI medium without D-glucose, 200 μg / mL L-ascorbic acid 2-phosphate (AA2-P), and 213 μg / mL bovine serum albumin;

[0037] Purified complete medium II includes: RPMI medium without D-glucose, 200 μg / mL L-ascorbic acid 2-phosphate (AA2-P), 213 μg / mL bovine serum albumin, 2 mM 2-Deoxy-D-glucose, and 5 mM sodium DL-lactate;

[0038] The present invention provides a purified culture medium for differentiated sinoatrial node-like cells, including purified complete culture medium I and purified complete culture medium II. Studies have found that sinoatrial node-like cells have low metabolic requirements and the ability to tolerate hypoxia stress and glucose deficiency. The sugar-free culture medium provided by the present invention can further purify the induced sinoatrial node-like cells in vitro. The present invention uses flow cytometry to detect the sinoatrial node-like cells (NKX2.5 in the BD group of the unpurified group and the purified group) on the 25th day of differentiation. - cTNT+ The results are shown in the figure, the control group NKX2.5 - cTNT + The cell ratio was 26.0±2%; the purified group NKX2.5 - cTNT + The cell ratio was 35.0±3%.

[0039] The method for purification culture using the above-mentioned purification medium comprises the following steps:

[0040] S1. Take out the differentiated sinoatrial node-like cells, add purified complete medium I, and culture for 48 hours;

[0041] S2. After 48 h, remove the cells, add purified complete medium II, and continue culturing for 2-4 days.

[0042] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are:

[0043] 1. The present invention proposes the use of a BMP signal selective inhibitor and a BMP signal activator in inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro. Studies have found that in the process of hESCs to differentiate into cardiomyocytes, unidirectional inhibition or activation of the BMP signaling pathway can promote the enrichment of sinoatrial node-like cells in vitro. However, through targeted experimental exploration, it was found that the temporal and bidirectional regulation of the BMP signaling pathway significantly promoted the differentiation of hESCs into sinoatrial node-like cells, and pacemaker cells with sinoatrial node electrophysiological characteristics can be efficiently obtained in vitro. The BMP signaling pathway is first inhibited by DMH1, thereby inhibiting the generation of FHF progenitor cells or promoting the generation of SHF progenitor cells, and on this basis, the sinoatrial node-specific signaling pathway is activated again to achieve the enrichment of sinoatrial node-like cells. Selectively inhibiting the BMP signaling pathway in the early stage of differentiation and then activating the BMP signaling pathway can significantly enhance the expression of sinoatrial node genes in the induced cells, greatly inhibiting the expression of atrial and ventricular muscles, but also increasing the expression of atrioventricular node and non-cardiomyocyte genes to a certain extent. Experimental research found that bidirectional regulation of BMP signaling (BD) significantly enhanced the expression of sinoatrial node genes in induced cells, while greatly inhibiting the expression of atrial and ventricular muscles; bidirectional regulation of BMP signaling (BD) also significantly increased NKX2.5 - / cTNT + Immunofluorescence staining showed that compared with the GIWI group, the BD group significantly upregulated TBX3 + / cTNT + , SHOX2 + / cTNT + 、TBX18 + / cTNT +and NKX2.5 - / cTNT + proportion.

[0044] 2. The method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro provided by the present invention comprises the following steps: step 1, on differentiation day 0, adding embryonic stem cells to differentiation complete medium I and culturing for 48 hours; step 2, on differentiation day 2, switching to differentiation complete medium II and culturing for 48 hours; step 3, on differentiation day 4-6, adding 2.5 μM DMH1 working solution to the cells for culturing; step 4, on differentiation day 6-7, switching to differentiation complete medium III; step 5, on differentiation day 7-9, adding 0.625 ng / ml BMP4 recombinant protein working solution to the cells; step 6, on day 9 to day 21, continuing to culture using differentiation medium III to obtain differentiated sinoatrial node-like cells. The operation is simple, the differentiation efficiency is high, and it is convenient for popularization and application.

[0045] 3. The present invention provides an induction differentiation medium, including differentiation complete medium I, differentiation complete medium II, DMH1 working solution, differentiation complete medium III and BMP4 recombinant protein working solution; based on the differentiation medium with clear chemical composition (including basic medium RPMI1640, L-ascorbic acid 2-phosphate and rice-derived recombinant human albumin), up to 95% of cardiomyocytes can be successfully differentiated in vitro. The induction differentiation medium has clear ingredients and has the advantages of simplicity, high efficiency, stability and high repeatability, which effectively overcomes the shortcomings of the in vitro induction method that requires the addition of multiple exogenous unknown proteins, and the differentiation is unstable and inefficient.

[0046] 4. The present invention provides a purification medium for differentiated sinoatrial node-like cells, including purified complete medium I and purified complete medium II. Studies have found that sinoatrial node-like cells have low metabolic requirements and the ability to tolerate hypoxic stress and glucose deficiency. The sugar-free medium provided by the present invention can further purify the induced sinoatrial node-like cells in vitro. The present invention uses flow cytometry to detect the sinoatrial node-like cells (NKX2.5 in the BD group of the unpurified and purified groups) on the 25th day of differentiation. - cTNT + The control group NKX2.5 - cTNT + The cell ratio was 26.0±2%; the purified group NKX2.5 - cTNT + The cell ratio was 35.0±3%. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 This is a diagram of the experimental model for the directed differentiation of hESC-H9 into cardiomyocytes.

[0048] Figure 2 This is the result of GO analysis of sinoatrial node enriched genes.

[0049] Figure 3 This is the expression trend diagram of the BMP signaling pathway during the directed differentiation of cardiomyocytes.

[0050] Figure 4 This is a diagram for exploring the optimal concentration of DMH1.

[0051] Figure 5 This is a diagram for exploring the optimal time window for DMH1.

[0052] Figure 6 This is a diagram for exploring the optimal concentration of BMP4 recombinant protein.

[0053] Figure 7 This is a diagram for exploring the optimal time window for BMP4 recombinant protein.

[0054] Figure 8 A diagram showing the effect of temporal regulation of BMP signaling on the differentiation fate of cells originating from the cardiogenic mesoderm.

[0055] Fig. 9 Flow cytometry was used to detect the expression of NKX2.5 in cells induced at day 21 of differentiation. - / cTNT + Graph of the cell generation ratio.

[0056] Fig.10 Figure 2 shows the culture results of the purified culture based on lactate metabolism and glucose starvation.

[0057] Fig.11 This is a test diagram of the electrophysiological characteristics of cardiomyocytes. DETAILED DESCRIPTION

[0058] The present invention will be described in detail below in conjunction with the accompanying drawings.

[0059] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0060] Product Name: Cardiomyocyte differentiation basal medium; manufacturer: Beijing Saibei Biotechnology Co., Ltd.

[0061] Product Name: Cardiomyocyte differentiation additive I; manufacturer: Beijing Saibei Biotechnology Co., Ltd.

[0062] Product Name: Cardiomyocyte differentiation additive II; manufacturer: Beijing Saibei Biotechnology Co., Ltd.

[0063] Product Name: Cardiomyocyte differentiation additive III; manufacturer: Beijing Saibei Biotechnology Co., Ltd.

[0064] Trade name: DMH1, manufacturer: Selleck Chemicals, item number: S7146-10mg.

[0065] Trade name: BMP4 recombinant protein, manufacturer: Peprotech, item number: 120-05-5.

[0066] Example

[0067] 1. Establish an experimental model for the directed differentiation of hiPSCs into cardiomyocytes:

[0068] The present invention adopts the currently common small molecule monolayer culture system, and the cardiomyocyte induction scheme with clear chemical composition is as follows Figure 1 As shown in A in the figure. This system is based on bidirectional regulation of the WNT signaling pathway to achieve in vitro differentiation of cardiomyocytes, and the differentiation medium is a cardiomyocyte differentiation medium with a clear chemical composition, which is conducive to our exploration of the regulatory effects of different intervention measures in the process of stem cell differentiation into cardiomyocytes. The above induction scheme successfully differentiated hESC-H9 into beating cardiomyocytes in a monolayer adherent culture mode ( Figure 1 B, Observation of the morphology of hESC-H9 and reticular cardiomyocytes (hESC-CM) under an inverted phase contrast microscope (scale bar: 200 μm). Beating cardiomyocytes (reticular or sheet-like) can be observed around day 7 to 8 of differentiation; cTNT in cells was detected by flow cytometry on day 21 of differentiation. + The ratio of cells, the results are as follows Figure 1 As shown in C, flow cytometry results show that cTNT in cells at day 21 of differentiation + The cell ratio was 85.9±3% (n≥4).

[0069] The specific operations are as follows:

[0070] hESC-H9 cardiomyogenic differentiation culture protocol

[0071] 1.1 Differentiation and culture of cardiomyocytes

[0072] 1) Preparation: Thaw the cardiomyocyte differentiation additives I, II and III stored in a -20°C refrigerator in a 4°C refrigerator. Centrifuge the cardiomyocyte differentiation additives instantaneously and add them to the cardiomyocyte differentiation basal medium according to the instructions to prepare cardiomyocyte differentiation complete medium I, II and III for use (stable storage at 4°C for 1 month).

[0073] 2) Differentiation day 0: Take out the hESC-H9 cells to be differentiated from the incubator and observe the cell morphology.

[0074] When the cells have good morphology, are evenly distributed and have a confluence of 75%-85%, they can be used for subsequent differentiation. Aspirate the waste liquid, wash the cells 1-2 times with an appropriate amount of PBS, then add complete cardiomyocyte differentiation medium I (about 4 ml per well of a 6-well plate; about 2 ml per well of a 12-well plate), return to the incubator and continue culturing for 48 hours, and accurately record the start time of differentiation, which is recorded as differentiation day 0.

[0075] 3) Differentiation Day 2: Remove the culture dish and observe the cell morphology. New cells can be seen covering the intercellular space and the nucleus is enlarged. Remove the complete cardiomyocyte differentiation medium I in the culture dish; add appropriate amount of PBS to wash the cells 1-2 times, continue to add complete cardiomyocyte differentiation medium II (about 4 ml per well of 6-well plate; about 2 ml per well of 12-well plate), and then return to the incubator to continue culturing for 48 hours, which is recorded as differentiation day 2.

[0076] 4) Differentiation Day 4: Remove the culture dish, observe the cell morphology, and remove the cardiomyocyte differentiation complete medium II; add appropriate amount of PBS to wash the cells 1-2 times, continue to add cardiomyocyte differentiation complete medium III (about 4 ml per well of 6-well plate; about 2 ml per well of 12-well plate), and then return to the incubator for continued culture, which is recorded as differentiation day 4.

[0077] 5) After the 4th day of differentiation: Replace the complete medium for differentiation of cardiomyocytes III every two days. The cells gradually become reticular and spindle-shaped. On the 8th to 10th day, beating cardiomyocytes can be seen in the form of a reticular or sheet.

[0078] 6) Maintaining culture: After differentiating into cardiomyocytes, the cells have a greater demand for energy metabolism. When the culture medium turns yellow, replace the culture medium in time and maintain the culture until the detection time point.

[0079] 1.2 Digestion and re-culture of cardiomyocytes

[0080] 1) Preparation of coating: coat the culture dish evenly with cardiomyocyte coating working solution and place it in an incubator overnight for later use.

[0081] 2) Cardiomyocyte digestion: Take out the culture dish to be digested, remove the cell waste liquid, add PBS to wash the cells 1-2 times, add cardiomyocyte digestion solution I (about 500ul per well of 6-well plate; about 250ul per well of 12-well plate) to completely cover the bottom of the culture dish, incubate in the incubator for 10-12 minutes; then take out the culture dish, under the microscope, it can be seen that the gaps between most cardiomyocytes are enlarged, polarity is lost, and the cells are round and bright. At this time, gently aspirate the cardiomyocyte digestion solution I, add the cardiomyocyte digestion solution II to continue digestion for 20-25 minutes (about 500ul per well of 6-well plate; about 250ul per well of 12-well plate); under the microscope, it can be seen that the cells are separated and suspended, then the digestion can be terminated.

[0082] 3) Terminate digestion: Use 2 ml of complete cardiomyocyte differentiation medium III to gently blow the bottom of the cell dish to completely remove the cardiomyocytes from the bottom and try to disperse the cell clumps. Transfer the cell suspension to a 15 ml centrifuge tube and centrifuge at 1000 rpm / 200 g for 5 min.

[0083] 4) Resuspending cardiomyocytes: After removing the supernatant, add cardiomyocyte differentiation complete medium III and gently blow to disperse the precipitate to mix the cell suspension evenly.

[0084] 5) Myocardial cell counting: The operation method is the same as stem cell counting.

[0085] 6) Re-seeding of cardiomyocytes: Prepare a suitable cell suspension using cardiomyocyte differentiation complete medium III according to the cell density required for the experiment. Gently pipette the cell suspension to mix well and then evenly seed the suspension in the culture dish. After the cells adhere to the wall, transfer the cells to the incubator and continue culturing.

[0086] 7) Replacement of myocardial cell medium: Observe the cell inoculation condition the next day, and replace with fresh myocardial cell differentiation complete medium III when the medium turns yellow, and return to the incubator for continued culture until the next experimental operation. Note: Myocardial cell digestion and inoculation will cause some myocardial cell death (about 20%).

[0087] 2. BMP signaling and myocardial differentiation of stem cells

[0088] Based on the differential transcriptome data of human and mouse sinoatrial nodes and adjacent atria published by Van EifVww et al., after GO (Gene Ontology) analysis, it was found that BMP signaling is closely related to the formation and function of the sinoatrial node ( Figure 2, indicating that RA, BMP and WNT signaling pathways are enriched in SAN). Recently, Churko JM et al. used complementary single-cell RNA-seq and RNA-seq technologies to analyze the in vitro stem cell differentiation process during the differentiation of stem cells into the heart. The present invention further studied his research and found that BMP secretion ligands increased with the progress of differentiation, while BMP4 increased with differentiation in the early stage and decreased with the progress of myocardial differentiation after the 4th day. In contrast, antagonists of the BMP signaling pathway increased with the progress of differentiation ( Figure 3 , by analyzing the data published by GSE81585, BMP ligands and antagonists increase with the progress of myocardial differentiation, and BMP4 ligand has a turning point in the process of myocardial differentiation). It can be seen that both BMP ligands and BMP antagonists are involved in myocardial differentiation and have their own specific time windows.

[0089] 3. Optimal regulatory concentration and optimal time window for BMP signaling pathway

[0090] Inhibiting or activating the BMP signaling pathway can promote the differentiation of hESC-H9 into sinoatrial node-like cells; the optimal concentration of DMH1 is 2.5μM / ml, and the optimal time window is 4-6 days of differentiation; the optimal concentration of BMP4 is 0.625ng / ml, and the optimal time window is 7-9 days of differentiation.

[0091] The specific operations are as follows:

[0092] 3.1 In vitro differentiation experimental method for temporal regulation of BMP signaling pathway

[0093] 3.11 Exploration of the optimal concentration of DMH1, a selective BMP signaling pathway inhibitor

[0094] 1) Preparation of mother solution: according to the instructions, add appropriate amount of DMSO to dissolve the small molecule DMH1 to prepare a mother solution with a concentration of 10 mM. Dispense appropriate amount of the mother solution into 1.5 ml EP tubes and store in a -20°C refrigerator for a long term.

[0095] 2) Preparation of working solution: Thaw the EP tube containing DMH1 mother solution at room temperature, and use complete cardiomyocyte differentiation medium III to prepare DMH1 mother solution into five concentration gradient working solutions of 5μM, 2.5μM, 1.25μM, 0.625μM, and 0.3125μM. Keep them at room temperature for use or store them at 4℃

[0096] 3) When the hESC-H9 cells from the same six-well plate grow to 85%, digest and subculture them to a 12-well plate (the cell suspension is evenly inoculated into the 12-well plate). When the cells grow to a confluence of 75%-85%, they can be used for subsequent differentiation.

[0097] 4) Differentiation day 0-4: the operation method is the same as above.

[0098] 5) Differentiation day 4: Take out the culture dish, aspirate the cardiomyocyte differentiation complete medium II, and divide the 12-well plate into 6 groups: GIWI, DMH15μM, DMH12.5μM, DMH11.25μM, DMH10.625μM, DMH10.3125μM; then put it back into the incubator for continued culture, which is recorded as differentiation day 4.

[0099] 6) After the 6th day of differentiation: replace the cardiomyocyte differentiation complete medium III every two days.

[0100] 7) Terminate the culture on the 21st day of differentiation and use the cells for subsequent studies according to experimental requirements.

[0101] On the 4th to 6th day of differentiation, GIWI was divided into the following experimental groups: DMH15μM, DMH12.5μM, DMH11.25μM, DMH10.625μM, DMH10.3125μM; after 21 days of induction of differentiation, sinoatrial node-related specific genes (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, IGFBP5) were detected by qPCR. The results showed that ( Figure 4 , A. The heat map shows that the expression of sinoatrial node-related genes is the highest when the concentration of DMH1 is 2.5μM. B. qPCR detection of the mRNA expression levels of sinoatrial node-specific genes (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, IGFBP5) in cells on the 21st day of differentiation (*P<0.05, **P<0.01, ***P<0.001, n=3). ), Compared with GIWI, 2.5μM DMH1 has the most significant effect in promoting the differentiation of sinoatrial node-like cells.

[0102] 3.12Exploration of the optimal time window for DMH1

[0103] 1) Preparation: Use complete cardiomyocyte differentiation medium III to prepare the mother solution of DMH1 into a 2.5 μM working solution and store it at room temperature or at 4°C (to be used within one week).

[0104] 2) Differentiation day 0-4: the operation method is the same as above.

[0105] 3) Differentiation Days 4-9: Add DMH1 working solution on differentiation days 4, 5, 6, 7, and 8, respectively. After 48 hours, switch back to complete cardiomyocyte differentiation medium III and continue culturing.

[0106] 4) After the 10th day of differentiation: replace the cardiomyocyte differentiation complete medium III every two days.

[0107] 5) Terminate the culture on the 21st day of differentiation and use the cells for subsequent research according to experimental requirements.

[0108] 4.3.4 Exploration of the optimal time window for BMP4 recombinant protein

[0109] 1) Preparation: Use complete cardiomyocyte differentiation medium III to prepare the mother solution of BMP4 recombinant protein into a working solution of 0.625 ng / ml and keep it at room temperature or store it at 4°C (need to be used within one week).

[0110] 2) Differentiation day 0-4: the operation method is the same as above.

[0111] 3) Differentiation Days 4-9: Add the working solution of BMP4 recombinant protein on differentiation days 4, 5, 6, 7, and 8, respectively. After 48 hours, switch back to complete cardiomyocyte differentiation medium III and continue culturing.

[0112] 4) After the 10th day of differentiation: replace the cardiomyocyte differentiation complete medium III every two days.

[0113] 5) Terminate the culture on the 21st day of differentiation and use the cells for subsequent research according to experimental requirements.

[0114] According to the previously found optimal DMH1 concentration of 2.5 μM, the following experimental groups were used: GIWI, DMH 4-6, DMH 5-7, DMH 6-8, DMH 7-9, and DMH 8-10; after 21 days of induction of differentiation, sinoatrial node-related specific genes (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, and IGFBP5) were detected by qPCR. The results showed that ( Figure 5 , A. The heat map shows that the expression of sinoatrial node-related genes is the highest when the optimal action time of DMH1 is 4-6. B. qPCR detected the mRNA expression levels of sinoatrial node-specific genes (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, IGFBP5) in cells on the 21st day of differentiation (*P<0.05, **P<0.01, ***P<0.001, n=3)). Compared with GIWI, the effect of using 2.5μM DMH1 on days 4-6 on promoting the differentiation of sinoatrial node-like cells was the most significant.

[0115] 3.13 Exploration of the optimal concentration of BMP4 recombinant protein, an activator of BMP signaling pathway

[0116] 1) Preparation of mother solution: according to the instructions, add an appropriate amount of sodium citrate solution to dissolve the BMP4 recombinant protein to prepare a mother solution with a molar concentration of 10 μg / ml; dispense an appropriate amount of the mother solution into 1.5 ml EP tubes and store in a -20°C refrigerator for a long term.

[0117] 2) Preparation of working solution: Thaw the EP tube containing BMP4 recombinant protein stock solution at room temperature, prepare the BMP4 recombinant protein stock solution into five working solutions with cardiomyocyte differentiation complete medium III: 10 ng / ml, 5 ng / ml, 2.5 ng / ml, 1.25 ng / ml, and 0.625 ng / ml, and keep them at room temperature or store at 4°C (the protein is unstable and must be used within 7 days).

[0118] 3) Differentiation day 0-4: the operation method is the same as above.

[0119] 4) After the 4th day of differentiation: remove the culture dish, aspirate the waste liquid, and divide the 12-well plate into 6 groups: GIWI, BMP410 ng / ml, BMP45 ng / ml, BMP42.5 ng / ml, BMP41.25 ng / ml, BMP40.625 ng / ml; then put it back into the incubator for continued culture, which is recorded as the 4th day of differentiation.

[0120] 5) Terminate the culture on the 21st day of differentiation and use the cells for subsequent research according to experimental requirements.

[0121] On the 4th to 6th day of myocardial differentiation, the cells were divided into the following experimental groups: GIWI, BMP10, BMP5, BMP2.5, BMP1.25, and BMP0.625; qPCR was used to detect the specific genes related to the sinoatrial node (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, and TNNT2) after 21 days of differentiation. Figure 6 ( Figure 6 A. The heat map shows that the expression of sinoatrial node-related genes was the highest when the BMP4 concentration was 0.625 ng / ml. 6B. qPCR detected the mRNA expression levels of sinoatrial node-specific genes (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, TNNT2) in cells at day 21 of differentiation (*P<0.05, **P<0.01, ***P<0.001, n=3). Compared with GIWI, 0.625 ng / ml BMP4 recombinant protein had the most significant effect on the sinoatrial node.

[0122] 3.14Exploration of the optimal time window for BMP signaling pathway activator-BMP4 recombinant protein

[0123] According to the previously found optimal BMP4 recombinant protein concentration of 0.625 ng / ml, the following experimental groups were used: GIWI; BMP4-6, BMP5-7, BMP6-8, BMP7-9, BMP8-10; after 21 days of induction of differentiation, sinoatrial node-related specific genes (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, HCN1) were detected by qPCR. The results are shown in Figure 7 (7A. The heat map shows that the expression of sinoatrial node-related genes was highest when the optimal action time of BMP4 recombinant protein was 7-9 days. 7B. qPCR detected the mRNA expression levels of sinoatrial node-specific genes (HCN4, SHOX2, TBX18, VSNL1, ISL1, SMOC2, CACNA2D2, HCN1) in cells on the 21st day of differentiation (*P<0.05, **P<0.01, ***P<0.001, n=3).) Compared with GIWI, the effect of using 0.625ng / ml BMP4 recombinant protein on promoting the differentiation of sinoatrial node-like cells at 7-9 days was the most significant.

[0124] 3.15 Temporal regulation of BMP signaling pathway in differentiation culture

[0125] 1) Preparation of working solution: Prepare the mother solutions of DMH1 and BMP4 recombinant proteins in complete cardiomyocyte differentiation medium III to prepare 2.5 μM DMH1 and 0.625 ng / ml BMP4 recombinant protein respectively; the working solution can be kept at room temperature or stored at 4°C (need to be used within one week).

[0126] 2) Differentiation day 0-4: the operation method is the same as above.

[0127] 3) Differentiation day 4-9: remove the culture dish, aspirate the waste liquid, and then change the medium according to the following 4 groups: control group (GIWI): add cardiomyocyte differentiation complete medium III on differentiation day 4-6, and add cardiomyocyte differentiation complete medium III on differentiation day 6-9;

[0128] DMH1 group: 2.5 μM DMH1 working solution was added on days 4-6 of differentiation, and cardiomyocyte differentiation complete medium III was added on days 6-9;

[0129] BMP4 group: cardiomyocyte differentiation complete medium III was added on differentiation day 4-7, and 0.625 ng / ml BMP4 recombinant protein working solution was added on differentiation day 7-9;

[0130] BD group: 2.5 μM DMH1 working solution was added on days 4-6 of differentiation, cardiomyocyte differentiation complete medium III was added on days 6-7, and 0.625 ng / ml BMP4 recombinant protein working solution was added on days 7-9.

[0131] 4) After the 9th day of differentiation: Replace the complete medium for cardiomyocyte differentiation III every two days. After differentiating into beating cells, the cells have a greater demand for energy metabolism, so the medium can be replaced when it turns yellow.

[0132] 3.16 Purification and culture of sinoatrial node-like cells

[0133] 1) Preparation: Thaw the purified additives I and II at 2-8°C according to the instructions, mix them after centrifugation, and then add additives I and II to the myocardial purification basal medium to form purified complete medium I and II (ratio 1:5, which can be stably stored at 2-8°C for 1 month).

[0134] 2) Take out the successfully differentiated sinoatrial node-like cells, remove the waste liquid, wash once with PBS phosphate buffer; add an appropriate amount of purified complete culture medium I, and return to the incubator to continue culturing for 48 hours.

[0135] 3) After 48 hours, remove the cardiomyocytes, remove the waste liquid, add an appropriate amount of purified complete culture medium II, return to the incubator for continued culture, and observe the cell morphology every day.

[0136] 4) After that, the purified complete medium II can be replaced regularly. The time to terminate the purified culture should be determined according to the morphology of the cardiomyocytes and miscellaneous cells. The total time for purified medium I and purified medium II is generally 4-6 days (2 days for purified medium I and 2-4 days for purified medium II). If it is observed that the beating frequency of the cardiomyocytes slows down or even gradually detaches from the wall, the purified culture should be terminated in time and the sinoatrial node maintenance complete medium should be replaced.

[0137] 4. Effects of bidirectional regulation of BMP signaling on cardiac lineage differentiation

[0138] Bidirectional regulation of BMP signaling (BD) significantly enhanced the expression of sinoatrial node genes in the induced cells, while greatly inhibiting the expression of atrial and ventricular muscles; bidirectional regulation of BMP signaling (BD) also significantly increased the generation ratio of NKX2.5- / cTNT+ cells (sinoatrial node-like cells); immunofluorescence staining showed that compared with the GIWI group, the BD group significantly upregulated the ratios of TBX3+ / cTNT+, SHOX2+ / cTNT+, TBX18+ / cTNT+ and NKX2.5- / cTNT+.

[0139] Specifically as follows:

[0140] 4.1 Bidirectional regulation of the BMP signaling pathway significantly enhanced the sinoatrial node phenotype in induced cells

[0141] The earliest step of cardiomyocyte differentiation involves the generation of mesoderm during gastrulation. In addition to differentiating into the well-known cardiomyocyte lineage, the cardiogenic mesoderm also gives rise to different types of non-cardiomyocyte lineage cells, including vascular smooth muscle cells, endothelial cells, fibroblasts, and epicardial cells.

[0142] To explore the role of bidirectional BMP signaling in cardiac lineage determination, we compared the effects of GIWI, DMH1, BMP4, and BD (DMH1+BMP4) on marker genes of each cardiac type in induced cells. qPCR was used to detect the expression of marker genes of all subtypes of cells originating from the cardiac mesoderm in cells at day 21 of differentiation. Figure 8 , Figure 8 A. Schematic diagram of the cardiac differentiation program that temporally regulates BMP signaling. Figure 8 B. Heat map of sinoatrial node cell biomarker genes (TBX3, ISL1, CACNB1, IGFBP5, GJC1, SCN3B, HCN1, HCN4, KCNJ3, SHOX2, TBX18, SMOC2, VSNL1, CACNA2D2, KCNN4); atrial myocyte biomarker genes (NF2R2, MYH6, MYL7, GJA5, KCNJ5, TBX5, NPPA); ventricular myocyte biomarker genes (I RX4, GJA1, CACNA1C, SCN5A, KCNQ1, NKX2.5, MYH7, MYL2); atrioventricular node cell biomarker genes (MSX2, TBX2, KCNE1, CPNE5); endothelial cell marker genes (PECAM1), vascular smooth muscle cell marker genes (VIM, PDGFRb, MYH11), fibroblast marker genes (TCF21, PDGFRa) and epicardial cell marker genes (UPK3B, WT1). Compared with GIWI, the DMH1 group upregulated sinoatrial node-enriched genes, downregulated ventricular-enriched genes, had little effect on atrial marker genes, and upregulated endothelial cells, smooth muscle markers, fibroblasts, epicardium and atrioventricular node marker genes; the BMP4 group generally upregulated sinoatrial node, atrium, ventricle, atrioventricular node, endothelial cells, smooth muscle markers, fibroblasts and epicardium marker genes; compared with other groups, the BD group significantly upregulated sinoatrial node-enriched genes, downregulated atrial and ventricular enriched genes, and upregulated endothelial cells, smooth muscle markers, fibroblasts, epicardium and atrioventricular node marker genes.

[0143] 4.2 Bidirectional regulation of BMP signaling pathway promotes the differentiation of sinoatrial node-like cells

[0144] The above research results suggest that bidirectional regulation of BMP signals significantly upregulated the expression levels of sinoatrial node cell marker genes; in order to further prove that BMP signals promote the in vitro differentiation of sinoatrial node-like cells, this experiment used flow cytometry to detect the differentiation ratio of sinoatrial node-like cells in cells on the 21st day of differentiation. Fig. 9 , Fig. 9 A. The BD group significantly upregulated the content of NKX2.5- / cTNT+ cells; Fig. 9 B. Statistical analysis of the generation ratio of NKX2.5- / cTNT+ in different experimental schemes. (*P<0.05, **P<0.01, ***P<0.001, n=3). Compared with the control group, the three schemes of DMH1, BMP4, and BD can increase the proportion of NKX2.5- / cTNT+ cells in cells on the 21st day of differentiation to varying degrees; and the BD group significantly increased the proportion of NKX2.5- / cTNT+ cells by 35.5±2% (n≥3).

[0145] 5. Purification culture based on energy metabolism further improves the generation ratio of sinoatrial node-like cells

[0146] Starting from the 20th day of differentiation, the sinus node-like cell purification medium was replaced for purification culture. After 2 days of culture without sugar (lactate (-); glucose (-)), and 3 days of culture with lactate replacement (lactate (+); glucose (-)), purification was terminated and replaced with sinus node-like cell maintenance medium.

[0147] Flow cytometry was used to detect the generation ratio of sinoatrial node-like cells (NKX2.5-cTNT+ cells) in the BD group of the unpurified and purified groups on the 25th day of differentiation. The results are shown in the figure. The ratio of NKX2-5-cTNT+ cells in the control group was 26.0±2%; the ratio of NKX2-5-cTNT+ cells in the purified group was 35.0±3%. The above results show that sugar-free purification culture based on lactate metabolism can increase the generation ratio of sinoatrial node-like cells in differentiated cells. The test results are as follows Fig.10 As shown, flow cytometry was used to detect the generation ratio of NKX2.5-cTNT+ cells in the CDM3 group, DMH1 group, BMP4 group, and BMP4+DMH1 group before purification (Before) and after purification (After) in cells at day 25 of differentiation (*P<0.05, **P<0.01, ***P<0.001, n=3).

[0148] 6. Bidirectional regulation of the BMP signaling pathway can produce cells with sinoatrial node electrophysiological characteristics

[0149] Whole-cell patch clamp was used to perform electrophysiological tests on cells at day 30 of differentiation, and the action potentials of 20 cardiomyocytes in the GIWI and BD groups were recorded.

[0150] The results are as follows Fig.11 It showed that we could detect three types of cell actions in both GIWI and BD groups ( Fig.11 A), we found that in the GIWI group, there were 2 cells with sinoatrial node-like action potentials, 7 cells with atrial-like action potentials, and 11 cells with ventricular-like action potentials; while in the BD group, there were 7 cells with sinoatrial node-like action potentials, 9 cells with atrial-like action potentials, and 4 cells with ventricular-like action potentials ( Fig.11 B).

[0151] Compared with the GIWI group, the cell beating recovery time of the BD group was earlier, and the impedance value, relaxation rate and upward rate were improved. After the addition of HCN ion channel inhibitor (Ivabradine), the beating rhythm of the GIWI group decreased significantly, while the beating rhythm of the BD group did not decrease significantly, indicating that the BD group was less affected by Ivabradine than the GIWI group. The typical action potentials of the three subtypes of cardiomyocytes were recorded in both the GIWI and BD groups; there were 11 cells with ventricular-like action potentials, 7 cells with atrial-like action potentials, and 2 cells with sinoatrial node-like action potentials in the GIWI group; there were 4 cells with ventricular-like action potentials, 9 cells with atrial-like action potentials, and 7 cells with sinoatrial node-like action potentials in the BD group.

[0152] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. The application of BMP signal selective inhibitor and BMP signal activator in inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro.

2. The use according to claim 1, characterized in that: The BMP signal selective inhibitor is DMH1; and / or, the BMP signal activator is BMP4 recombinant protein.

3. The use according to claim 1, characterized in that: The BMP signal selective inhibitor is used on the 4th to 6th day of inducing directed differentiation; the mass concentration of the BMP signal selective inhibitor in the differentiation induction medium is 2-3 μM, preferably, the mass concentration of the BMP signal selective inhibitor in the differentiation induction medium is 2.5 μM.

4. The use according to claim 1, characterized in that: The BMP signal activator is used on the 7th to 9th day of inducing directed differentiation; the mass concentration of the BMP signal activator in the differentiation induction medium is 0.5-1 ng / ml, preferably, the mass concentration of the BMP signal activator in the differentiation induction medium is 0.625 ng / ml.

5. A differentiation induction medium, characterized in that: The differentiation induction medium includes differentiation complete medium I, differentiation complete medium II, DMH1 working solution, differentiation complete medium III and BMP4 recombinant protein working solution; Among them, differentiation complete medium I includes: RPMI 1640 basal medium, 500 μg / mL L-ascorbic acid 2-phosphate (AA2-P), 213 μg / mL bovine serum albumin and 5 μM CHIR99021; Differentiation complete medium II included: RPMI 1640 basal medium, 500 μg / mL L-ascorbic acid 2-phosphate (AA2-P), 213 μg / mL bovine serum albumin, and 2 μM Wnt-C59; Differentiation complete medium III includes: RPMI 1640 basal medium, 500 μg / mL L-ascorbic acid 2-phosphate (AA2-P), 213 μg / mL bovine serum albumin; The DMH1 working solution is differentiation complete medium III including DMH1 at a mass concentration of 2.5 μM; The BMP4 recombinant protein working solution is a differentiation complete medium III including the BMP4 recombinant protein at a mass concentration of 0.625 ng / ml.

6. Use of the differentiation induction medium as claimed in claim 5 in inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro.

7. A method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro, characterized in that: Step 1: On differentiation day 0, embryonic stem cells were added to complete differentiation medium I and cultured for 48 h; Step 2: On the second day of differentiation, switch to differentiation complete medium II and culture for 48 hours; Step 3: On the 4th to 6th day of differentiation, the cells were cultured by adding 2.5 μM DMH1 working solution; Step 4: On the 6th to 7th day of differentiation, switch to differentiation complete medium III; Step 5: On differentiation day 7-9, add 0.625 ng / ml BMP4 recombinant protein working solution to the cells; Step 6: From day 9 to day 21, continue culturing using differentiation medium III to obtain differentiated sinoatrial node-like cells.

8. The method for inducing embryonic stem cells to differentiate into sinoatrial node-like cells in vitro according to claim 7, characterized in that: Embryonic stem cells are human embryonic stem cells.

9. A purification culture medium for differentiated sinoatrial node-like cells, characterized in that: Comprising purified complete medium I and purified complete medium II; Wherein, the purified complete medium I comprises: RPMI medium without D-glucose, 200 μg / mL L-ascorbic acid 2-phosphate (AA2-P), and 213 μg / mL bovine serum albumin; Purified complete medium II includes: RPMI medium without D-glucose, 200 μg / mL L-ascorbic acid 2-phosphate (AA 2-P), 213 μg / mL bovine serum albumin, 2 mM 2-Deoxy-D-glucose and 5 mM sodium DL-lactate.

10. A method for purification culture using the purification medium according to claim 9, characterized in that: The following steps are involved: S1. Take out the differentiated sinoatrial node-like cells, add purified complete medium I, and culture for 48 hours; S2. After 48 h, remove the cells, add purified complete medium II, and continue culturing for 2-4 days.

Citation Information

Cited By

  • SAN-like cells and method for differentiating pluripotent stem cells into SAN-like cells in vitro

    CN122278754A